Catch Bio

Cover Block

PUBLIC

Field	Value
Name	Catch Bio
Tagline	Maps cancer risk factors and builds personalized screening protocols and action plans
Headquarters	Chicago, Illinois
Founded	2023
Stage	Seed
Business Model	B2C
Industry	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Funding Label	Seed
Total Disclosed	~$2,000,000

Links

PUBLIC

• Website: https://app-dev.catchbio.com/

Executive Summary

PUBLIC

Catch Bio is a Chicago-based seed-stage healthtech company building a consumer platform that quantifies an individual's lifetime cancer risk and translates that risk into a personalized screening protocol and prevention plan [Crunchbase] [Kahn Longevity Center]. The company was incorporated in 2023 and raised approximately $2.0 million in an equity round filed in January 2025, according to a Form D-style filing aggregator [formds.com, Jan 2025]. Its product positioning sits at the intersection of two trends investors have been tracking closely: the consumerization of preventive medicine and the growing willingness of self-pay patients to fund screening that sits outside standard insurance pathways [f4.fund]. The company's pitch, as described by third-party writeups, is to map risk factors across every major cancer and convert that map into an actionable plan covering screening cadence, biomarker tests, and behavior changes [Crunchbase] [f4.fund]. Founder identities, named lead investors, and traction metrics are not present in the public record reviewed for this report, which constrains the diligence picture and is addressed in the private half. Over the next 12 to 18 months, the items worth tracking are: a named clinical or longevity-clinic distribution partner, evidence of paid user cohorts, and any disclosure around the medical advisory bench that underwrites its risk model. The opportunity is real, the public footprint is thin, and the seed size suggests a deliberately lean build rather than a heavily marketed launch.

Data Accuracy: YELLOW -- Founding year and seed amount corroborated across PitchBook, Crunchbase, and formds.com; product claims rely on company-adjacent writeups rather than independent press.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2C
Industry / Vertical	Healthtech, cancer prevention
Technology Type	Biotech / Life Sciences, risk-modeling software
Geography	North America (HQ Chicago, IL)
Growth Profile	Venture Scale
Funding	~$2.0M seed (Jan 2025) [formds.com, Jan 2025]

Company Overview

PUBLIC

Catch Bio was founded in 2023 and is headquartered in Chicago, Illinois, according to PitchBook's company profile [PitchBook]. The company operates under the legal entity Catch Bio, Inc., the name listed on its January 2025 securities filing [formds.com, Jan 2025]. Beyond the entity name, founding year, and a seed-stage equity raise of approximately $2,000,000 dated January 10, 2025, the company has left a deliberately light public footprint: there is no press release archive, no announced executive team page in the captured sources, and the product site referenced in Crunchbase and the company's own listing resolves to a development subdomain rather than a public marketing site [Catch Bio] [Crunchbase].

The milestone timeline that can be assembled from primary filings and database listings is therefore short. Incorporation and product framing took shape in 2023 [PitchBook]. A writeup from the Kahn Longevity Center, a Detroit-area integrative cardiology clinic, positioned Catch as "the first platform to quantify your lifetime cancer risk and turn it into an actionable, personalized prevention strategy," suggesting at least one clinical channel partner or champion has engaged with the product [Kahn Longevity Center]. The seed equity filing in January 2025 marks the only confirmed financing event [formds.com, Jan 2025].

For a company that has chosen a consumer-facing posture in a regulated category, the lean public surface is notable but not unusual at seed. Many preventive-health startups operate in a quiet beta period while they assemble the medical, legal, and reimbursement scaffolding that a launch in oncology-adjacent screening requires. Investors approaching the company should expect that the substantive operating detail, founders, clinical advisors, payer or clinic relationships, and early cohort data, sits behind a direct conversation rather than in the public record.

Data Accuracy: YELLOW -- Entity, HQ, and founding year confirmed by PitchBook and the SEC-style filing on formds.com; milestone narrative limited by the absence of independent press coverage.

Product and Technology

MIXED

The product, as described across third-party listings, is a personalized cancer risk assessment service. Crunchbase summarizes it as a platform that "maps risk factors for every major cancer and builds an optimal screening protocol and personalized action plan" [PUBLIC] [Crunchbase]. The fund profile from f4.fund expands on that, describing a "comprehensive cancer risk assessment service that evaluates individual risk factors and biomarkers to help users understand and reduce their cancer risk through personalized action plans" [PUBLIC] [f4.fund]. The Kahn Longevity Center describes the output as a quantified lifetime cancer risk paired with an actionable, personalized prevention strategy [PUBLIC] [Kahn Longevity Center]. Taken together, the product appears to combine three components: an intake that captures family history, lifestyle, and biomarker inputs; a risk model that scores lifetime cancer risk by site or in aggregate; and a recommended protocol covering screening cadence and modifiable risk-factor changes.

The underlying technology stack is not disclosed in any captured source. Risk-modeling products in this category typically combine validated epidemiological models (for example, Gail or Tyrer-Cuzick for breast cancer, and analogous site-specific tools) with proprietary weighting layers and a software UX wrapped around them. Whether Catch is using published models, building proprietary ones, or layering an LLM interface on top is not stated in the public record. There is no GitHub presence captured, no developer documentation, and no published validation study tied to the company's name. The product URL surfaced in the research, app-dev.catchbio.com, is a development subdomain rather than a production marketing site, which is consistent with a pre-launch or limited-access posture [PUBLIC] [Catch Bio].

For regulated-category investors, the diligence questions that follow naturally are: which risk models are being used and under what license, whether any component of the product is positioned as clinical decision support (which would invite FDA scrutiny), how biomarker data is collected (lab partner, at-home kit, or imported from existing patient records), and whether the consumer relationship is direct-pay or routed through a clinical partner such as the longevity clinic that has publicly endorsed the platform.

Data Accuracy: ORANGE -- Product description triangulated across three independent listings, but no independent product review, demo writeup, or technical disclosure is available; tech stack is undisclosed.

Market Research and Opportunity

PUBLIC

The market matters now because cancer screening is moving from an episodic, payer-driven event into a continuous, consumer-funded protocol, and the early commercial winners in adjacent longevity categories have shown that self-pay buyers will support meaningful subscription pricing.

Catch Bio sits in the consumer cancer-prevention segment of healthtech, a category that overlaps with three larger and better-documented markets: clinical cancer screening, longevity and preventive medicine memberships, and consumer genetic and biomarker testing. The captured sources do not include a third-party TAM figure specific to consumer cancer-prevention software, so any sizing here must be drawn from analogous categories rather than presented as a confirmed Catch Bio TAM. The endorsement from the Kahn Longevity Center, a clinic operating in the integrative and preventive medicine space, situates Catch within the longevity-clinic ecosystem that has expanded rapidly alongside players like Function Health, Superpower, and Ezra [Kahn Longevity Center].

Demand drivers visible in the cited research are straightforward. The Kahn Longevity Center frames Catch as addressing the gap between standard age-based screening guidelines and a personalized, risk-stratified protocol [Kahn Longevity Center]. The f4.fund profile emphasizes the combination of risk factors and biomarkers as the input layer, signaling that the product is designed to absorb the increasing volume of consumer biomarker data that adjacent companies are already generating [f4.fund]. On the macro side, growing public awareness of early-onset cancer trends and a broader consumer willingness to pay out-of-pocket for preventive testing both work in the company's favor.

The regulatory layer is the single largest external variable. Risk-scoring products that stop short of diagnosis generally sit outside FDA device regulation, but any product that recommends a specific screening test or interprets a biomarker result can edge into clinical decision support territory and trigger oversight. State-level rules around the corporate practice of medicine also shape whether the company can offer recommendations directly or must route them through a contracted physician network. None of the captured sources indicate how Catch has structured these questions.

Sizing reference	Value	Source
Catch Bio seed raise	~$2.0M (Jan 2025)	[formds.com, Jan 2025]
Catch Bio founding year	2023	[PitchBook]

Confirmed numerics on Catch Bio itself are limited to the round size and founding year, so any market view has to be built from analogous categories rather than from company-disclosed TAM. The directional case, that consumers are paying more for personalized prevention and that cancer is the highest-stakes node in that map, is supported by the cited endorsements but is not yet quantified in the public record for this specific company.

Data Accuracy: ORANGE -- Company-level figures confirmed; market-level sizing is directional and drawn from analogous categories rather than a Catch Bio-specific third-party report.

Competitive Landscape

MIXED

Catch Bio is positioned as a software-first cancer risk platform in a category where the alternatives are split between full-stack diagnostic companies, longevity-clinic memberships, and traditional clinical pathways.

The competitive map can usefully be split into three buckets. First, full-stack early-detection diagnostic companies such as multi-cancer early detection (MCED) blood-test providers occupy the high end of the consumer cancer category and operate as test-centric businesses with a software wrapper. They have heavier capital requirements, longer regulatory pathways, and clearer reimbursement targets, but their consumer narrative competes for the same attention Catch is courting. Second, longevity-membership platforms that bundle broad biomarker panels with concierge interpretation increasingly include cancer risk scoring as one feature among many; these are the most direct attention competitors for a self-pay consumer evaluating where to spend their preventive-health budget. Third, the legacy alternative is the standard clinical pathway: an annual physical, age-based screening guidelines, and ad hoc genetic testing when family history triggers it [PUBLIC].

Where Catch appears to have a defensible edge, based on the cited positioning, is focus. By concentrating on cancer specifically rather than offering a general longevity dashboard, the company can build a deeper risk model and a sharper consumer message [PUBLIC] [Crunchbase] [f4.fund]. Focus is a perishable advantage in this category, however: the broader longevity platforms have larger user bases and can add a cancer module quickly if the demand signal is strong. Whether Catch's edge is durable will depend on two things the public record does not yet show: a proprietary data layer (for example, an integrated biomarker pipeline or a validated proprietary risk model) and a distribution lock-in (for example, exclusive clinic partnerships or an employer channel) [PRIVATE diligence item].

Where the company is most exposed is on the brand and trust axis. Cancer is the highest-stakes consumer health category, and the buyers Catch needs are the same buyers that incumbent diagnostic brands and well-funded longevity memberships are already addressing with eight- and nine-figure marketing budgets. A $2.0 million seed does not buy a national consumer brand; it buys a focused product build and a small set of channel experiments. The risk is that even a well-built product struggles to reach the consumer through paid acquisition and has to rely on clinical-partner distribution to scale [PUBLIC].

The most plausible 18-month competitive scenario splits along distribution. Winner if Catch lands a multi-clinic distribution agreement with a longevity-clinic network or a self-insured employer pilot, because either channel collapses the customer-acquisition cost problem and creates a defensible cohort. Loser if the company tries to run a direct-to-consumer paid acquisition motion against the longevity memberships and the MCED diagnostics brands without a meaningful budget advantage, because the unit economics of cold consumer acquisition in preventive health rarely work at seed-stage scale.

Opportunity

PUBLIC

The size of the prize, if Catch executes against the framing in its public materials, is meaningfully larger than its seed cheque suggests, because cancer is the single most emotionally salient category in preventive health and the willingness-to-pay tail in that category is long.

The headline opportunity. The largest plausible outcome for Catch is becoming the default risk-stratification layer for consumer cancer prevention: the software that sits between a person's biomarker and history data on one side and the screening, behavior, and biomarker recommendations on the other [Crunchbase] [f4.fund]. The Kahn Longevity Center's framing of Catch as "the first platform to quantify your lifetime cancer risk and turn it into an actionable, personalized prevention strategy" is the kind of category-defining language that, if validated by independent clinical partners and consumer adoption, could position the company as the reference layer for cancer in the same way that broader longevity platforms have positioned themselves as the reference layer for biological age [Kahn Longevity Center]. The path is reachable rather than aspirational because the input data Catch needs (family history, lifestyle, biomarkers) is already being captured by adjacent platforms, and a focused product can interoperate rather than compete head-on.

Growth scenarios.

Scenario	What happens	Catalyst	Why it's plausible
Clinic-embedded risk layer	Catch becomes the cancer module inside longevity and preventive clinics, paid for by the clinic and surfaced to patients as part of the workup	A second and third named clinic partner following the Kahn Longevity Center engagement	The Kahn endorsement demonstrates clinical receptivity and the pricing model fits clinic economics [Kahn Longevity Center]
Direct-to-consumer subscription	Catch builds a self-pay membership around an annual updated cancer risk plan and screening reminders	A demonstrated cohort with retention metrics that justify paid acquisition spend	Adjacent self-pay preventive-health products have shown consumers will pay for personalized protocols [f4.fund]
Employer or payer channel	A self-insured employer or progressive payer contracts Catch as a covered benefit for risk-stratified screening	A pilot study showing increased screening adherence or earlier-stage detection in a defined cohort	Employers are actively buying preventive-health point solutions and cancer is a top driver of medical spend

What compounding looks like. The flywheel that turns one win into the next in this category is data. Every additional user who completes an intake and links biomarker results improves the risk model, which improves the recommendation quality, which improves retention and word-of-mouth, which lowers acquisition cost. A clinic-embedded distribution model accelerates that loop because clinics deliver high-intent users at near-zero marginal acquisition cost and validate the recommendations in a clinical setting.

The size of the win. Public comparables in adjacent categories suggest the upper bound is large. Consumer longevity and preventive-health platforms have raised at valuations in the hundreds of millions on the strength of subscription cohorts, and the multi-cancer early detection diagnostic category supports public-market and late-stage private valuations measured in billions. If Catch reaches the clinic-embedded risk layer outcome described above, a comparable outcome would be a mid-nine-figure platform business serving a defined longevity-clinic and self-pay consumer market (scenario, not a forecast). The realistic base case at the current evidence level is much more modest: a focused seed-funded team that proves a clinical partnership model, raises a Series A on the back of cohort data, and either scales independently or becomes the cancer module inside a larger preventive-health platform.

Data Accuracy: ORANGE -- Opportunity framing is grounded in cited product positioning and one named clinical endorsement; scale scenarios are explicitly labeled as scenarios rather than forecasts because no traction or revenue figures are in the public record.

Sources

PUBLIC

1. [PitchBook] Catch Bio 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/711218-71

2. [Crunchbase] Catch Bio - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/catch-bio

3. [f4.fund] Catch Bio - Healthcare & Digital Health | https://f4.fund/startups/catchbio

4. [Kahn Longevity Center] CATCH BIO: The World's First Cancer Prevention Platform | https://www.kahnlongevitycenter.com/blog/catch-bio-the-worlds-first-cancer-prevention-platform

5. [Catch Bio] Catch Bio product site | https://app-dev.catchbio.com/

6. [formds.com, Jan 2025] Catch Bio, Inc. - fund raising filing | https://formds.com/issuers/catch-bio-inc

7. [Crunchbase] Seed Round - Catch Bio | https://www.crunchbase.com/funding_round/catch-bio-seed--11681966

8. [teeming.ai] Catch Bio | https://teeming.ai/c/catch-bio/d3d072e7-50e0-403e-84d5-6df871b2490d